| R × 1 |
Does radiotherapy improve the survival of people with MPM? (See also RS ×7). |
| R ×2 |
Does surgery (EPP or P/D) improve the survival of MPM patients? |
| R ×3 |
Does chemotherapy or so-called targeted therapies improve the survival of patients with MPM? |
| R ×4 |
Do immunologically based treatments improve the survival of patients with MPM? |
| R ×5 |
Does complementary or alternative medicine (CAM) improve the survival of people with MPM? |
| R ×6 |
Does combined modality (surgery, radiotherapy and/or chemotherapy in any combination) improve the survival of people with MPM? If so, what is the optimal sequencing of treatments? |
| R ×7 |
Does IMRT or other radiotherapy modifications improve survival of MPM patients? |
| R ×8 |
Does radiotherapy reduce tumour seeding after biopsy procedures in malignant mesothelioma? Does prophylactic radiotherapy to prevent intervention tract seeding produce any meaningful impact on the natural history of MPM? |
| R ×9 |
For chemotherapy, what is the optimal timing for the delivery of chemotherapy, for MPM? |
| R ×10 |
For chemotherapy, what are the optimal agents(s) for MPM? |
| R ×11 |
For chemotherapy, what is the optimal number of cycles for MPM? |
| R ×12 |
For chemotherapy, does maintenance treatment improve survival in MPM? |
| R ×13 |
Does second-line chemotherapy improve outcomes (survival, quality of life, symptoms) in MPM? |
| R × S7 |
What is the evidence that radiotherapy can provide symptom palliation for patients with malignant mesothelioma, in particular pain, mass effect, dyspnoea? |
| R × S8 |
Is there a relationship between radiotherapy dose and/or duration and symptom response? |
| R × S9 |
Are there disease and patient factors which predict for likelihood of symptom response to radiotherapy, such as performance status, age, histology? |
| R × S10 |
Is palliative radiotherapy for malignant mesothelioma associated with toxicity? |
